Kura Oncology's Darlifarnib Shows 67% Response in Pancreatic Cancer, Outlines Broad KRAS Strategy
Summary
Kura Oncology presented compelling preliminary Phase 1a data for darlifarnib in combination with adagrasib, achieving objective response rates of 67% in pancreatic cancer, 50% in NSCLC, and 29% in KRAS inhibitor-naïve colorectal cancer. This builds on prior positive data, reinforcing darlifarnib's potential as a foundational platform for KRAS-mutant cancers. The company outlined a new platform study to accelerate development across multiple combinations, with the first new Phase 1a trial expected in early 2027. This strategic expansion and strong clinical activity significantly de-risk a key pipeline asset.
At the time of this announcement, KURA was trading at $9.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $796.3M. The 52-week trading range was $5.45 to $12.49. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.